Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine + NY-ESO-1 peptide vaccine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|Anti-NY ESO-1 mTCR PBL||NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL||Anti-NY ESO-1 mTCR PBL are peripheral blood lymphocytes that have been transduced with a retroviral vector expressing a T-cell receptor that targets NY-ESO, which may enhance anti-tumor immune response against NY-ESO-expressing tumor cells (PMID: 24598449).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|NY-ESO-1 peptide vaccine||NY-ESO-1 peptide vaccine is a vaccine against cancer-testis antigen (NY-ESO-1), which may enhance the humoral and cytotoxic immune responses against tumor cells expressing NY-ESO-1 (PMID: 12488431, PMID: 17652518).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01697527||Phase II||Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine + NY-ESO-1 peptide vaccine||Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies||Active, not recruiting|